High level of RNF187 contributes to the progression and drug resistance of osteosarcoma

Conclusions: Our results indicate that Elevated RNF187 expression is a new adverse outcomes marker for OS patients and may be used as a new therapeutic target of OS.

Source: Journal of Cancer - July 2, 2020 Category: Cancer & Oncology Authors: Wen-Bing Wan, Kai Wu, Kun Peng, Zhi-Qiang Qiu, Zhi-Bin Duan, Xiang Chen, Ze-Min Xu, Ke Cheng, Jiang-Ming-Hao Zhao, Qing-Ming Shi Tags: Research Paper Source Type: research